stockrow
Saturday 7 November 2026
Export BBLG’s income statement to Excel — free account
Bone Biologics Corp.
BBLG Healthcare Biotechnology
- EPS
- +55.3%
- Free cash flow
- +9.99%
Quarter to September 2026, against a year earlier
0.33
0.01
+3.13%
Follow BBLG
Alert me
Bone Biologics Corp. (BBLG) P/E ratio
Bone Biologics Corp. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| BBLG Bone Biologics Corp. | n/m |
| BDRX Biodexa Pharmaceuticals PLC Unsponsored ADR compare | n/m |
| ARTL Artelo Biosciences, Inc. compare | n/m |
| MTNB Matinas Biopharma Holdings, Inc. compare | n/m |
| VBIO Valion Bio, Inc. compare | n/m |
| LABT Lakewood-Amedex Biotherapeutics Inc. compare | n/m |
| JAGX Jaguar Animal Health, Inc. compare | n/m |
| BPTH Bio-Path Holdings, Inc. compare | n/m |
| PTIX Atrinsic Inc. compare | 0.2× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)